-
Lancet oncol: Efficacy and safety of pembrolizumab combined with cetuximab in the treatment of relapsed/metastatic HNSCC
Time of Update: 2021-05-21
Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) as a single agent and combined cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) have shown treatment active.
-
The best biomarkers for targeted therapy of ovarian cancer
Time of Update: 2021-05-21
The latest SOLO-1 data shows that for newly diagnosed ovarian cancer patients with BRCA mutations, the benefits of maintenance therapy with the PRAP inhibitor olaparib for 2 years can continue until the end of the treatment, and nearly half of the patients will be treated after 5 years.
-
Nature Sub-Journal: Gu Zhen's research group develops anti-cancer patches, which can catalyze the production of anti-cancer drugs in tumors
Time of Update: 2021-05-21
The research team used polyvinyl alcohol (PVA) as the matrix of the microneedle patch, mixed with titanium dioxide nanosheets deposited by palladium nanoparticles, and prepared a bio-orthogonal catalytic device that can increase efficiency, reduce toxicity, and is easy to use (Figure 2) The anti-cancer drugs can be produced in situ by catalyzing the place where the patch is used.
-
One Article | From the latest consensus, how should patients with lung cancer brain metastases be treated?
Time of Update: 2021-05-21
In the FLAURA study, the analysis of the brain metastasis subgroup of patients showed that the median PFS benefit of osimertinib in the first-line treatment of EGFR gene-sensitive mutation-positive NSCLC patients was significantly better than the first-generation EGFR-TKIs (19.
-
The Oncologist: Safety analysis of Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer: An update from the PALOMA series of 5-year follow-up comprehensive analysis
Time of Update: 2021-05-21
Through 5 years of long-term comprehensive analysis, Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer is proved to be a safe treatment.
Through 5 years of long-term comprehensive analysis, Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer is proved to be a safe treatment.
-
Master the diagnosis and treatment of newly diagnosed follicular lymphoma in one article
Time of Update: 2021-05-21
The results of a randomized clinical study of newly diagnosed patients with advanced FL with indications for treatment showed that [6], in the use of immunochemotherapy and up to 2 years of maintenance therapy, the new CD20 monoclonal antibody otuzumab was used ( Obinutuzumab) significantly improved patients' PFS compared with rituximab.
-
The light of the original research: the full text of the top international journal of the AHELP study of apatinib was published
Time of Update: 2021-05-21
On May 7, 2021, the "Prospective, randomized, double-blind, double-blind, second-line apatinib treatment of advanced hepatocellular carcinoma (HCC) for the second-line and above apatinib treatment of advanced hepatocellular carcinoma (HCC), led by Professor Qin Shukui of Nanjing Jinling Hospital The placebo-controlled national multi-center Phase III clinical trial (AHELP) was published in full online in the top international academic journal THE LANCET Gastroenterology & Hepatology.
-
PARP inhibitors are safe and effective for maintenance treatment of advanced pancreatic cancer; dual immunization combined with chemotherapy has significant benefits in the first-line treatment of NSCLC|Tumor News
Time of Update: 2021-05-21
*Only for medical professionals to read for reference 1 minute a day, give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add to
-
Liver Cancer: Patients with advanced liver cancer with vascular tumor thrombi may choose hepatic artery infusion chemotherapy + radiotherapy!
Time of Update: 2021-05-21
Patients with advanced HCC with non-alcoholic fatty liver diabetes mellitus combined with portal vein trunk or two-lobe tumor thrombosis (Vp4) have worse overall survival time with thrombosisThis study aims to clarify the prognosis of hepatic arterial infusion chemotherapy (HAIC) combined with radiotherapy (RT) in patients with advanced liver cancer combined with Vp4, and analyze the factors that affect the prognosis.
-
Current and future prospects of PD-1/PDL-1 inhibitors in cancer immunotherapy
Time of Update: 2021-05-21
Compared with healthy individuals, PD-L1 is significantly up-regulated in patients with advanced NSCLC, and PD-L1 is highly expressed in breast cancer primary cancer cells, and other facts indicate that this type of cancer may benefit from immune checkpoint therapy.
-
Can heat shock treat leukemia?
Time of Update: 2021-05-21
The molecular mechanism of arsenic trioxide and all-trans retinoic acid in the treatment of APL is to target the reduction of the stability of the PML/RARα fusion protein to promote the differentiation and apoptosis of leukemia cells.
-
Professor Cheng Ying: Osimitinib adjuvant treatment indications were approved, rewriting the domestic operable EGFR mutation treatment model
Time of Update: 2021-05-21
Multiple previous meta-analysis indicated that only N2 patients receiving adjuvant radiotherapy have a trend of OS benefit, 2020 The results of the Lung ART study published at the European Society of Medical Oncology (ESMO) meeting in 2016 showed that for patients with IIIA-N2, adjuvant radiotherapy did not have significant benefits of disease-free survival (DFS) and OS, and increased cardiopulmonary-related adverse events Therefore, people have been trying to find more effective adjuvant treatment methods and models.
-
Express | Triple-negative breast cancer disease control rate reaches 95%, TROP2-ADC preliminary clinical results are positive
Time of Update: 2021-05-21
▎The content team editor of WuXi AppTec recently, researchers announced for the first time that the antibody-conjugated drug (ADC) datopotamab deruxtecan (Dato-DXd), which targets TROP2, will be used in a phase 1 clinical trial for the treatment of triple-negative breast cancer (TNBC).
-
The first leukemia child to receive CAR-T treatment, cancer-free for nine years!
Time of Update: 2021-05-21
After receiving treatment, Emily developed cytokine release syndrome, also known as cytokine storm, which is a common acute side effect of CAR-T therapy.
Pineapple Factor "The first child cured by CAR-T therapy, has survived cancer-free for 9 years!
-
Nat Commun: Unexpectedly, ultraviolet light can inhibit the invasion of melanoma
Time of Update: 2021-05-21
Although the relationship between ultraviolet light and the incidence of melanoma has been confirmed, controversial clinical studies have shown that sun exposure or sun damage to the dermis is associated with an increase in the survival rate of melanoma.
-
Multiple metastases of advanced lung cancer, life is hanging by a thread; the combination of immunization and immunization, combined with two swords, will come to life from desperation
Time of Update: 2021-05-21
Therefore, on the 6th day after the end of whole brain radiotherapy, the patient received pembrolizumab Monoclonal antibody 200mg q3w intravenous infusion of anti-tumor immunotherapy, combined with disulumab 120mg q4w subcutaneous injection for bone protection therapy, while receiving symptomatic support such as controlling blood pressure and blood sugar, improving renal function, and regulating intestinal flora.
-
The most complete summary: Do you need adjuvant treatment after lung cancer surgery?
Time of Update: 2021-05-21
The Phase IB ADAURA study [9] showed that the adjuvant treatment of osimertinib for 3 years after complete tumor resection of EGFR mutation-positive stage IB patients can reduce the risk of disease recurrence or death by 61%.
-
Cancer cells put "poison" to suppress T cells!
Time of Update: 2021-05-21
They found that extracellular vesicles (TEVs) containing miR-424 secreted by intestinal cancer cells can be taken up by infiltrating immune cells in the tumor microenvironment, resulting in a decrease in the expression of CD28 and CD80 of T cells and dendritic cells (DCs).
-
The third-generation CAR-T of Mustang Biotech obtains US FDA approval for IND application to initiate clinical research | Yimai Meng broke the news
Time of Update: 2021-05-21
Initiated phase 1/2 clinical research to develop the safety, tolerability and safety of MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) Effectiveness.
-
Molecular Cancer | Fan Jia and Shi Guoming from Fudan University discover a new mechanism for the progression of liver cancer
Time of Update: 2021-05-21
On May 13, 2021, Fudan University Fan Jia and Shi Guoming jointly published a study titled "CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity" in Molecular Cancer (IF=15.
